5-(tert-butyl)imidazolidine-2,4-dione | 169961-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5-(tert-butyl)imidazolidine-2,4-dione
• 英文别名: 5-tert-butyl-imidazolidine-2,4-dione；5-tert-Butyl-imidazolidin-2,4-dion；5-Tert-butylimidazolidine-2,4-dione
• CAS: 169961-91-5
• 化学式: C₇H₁₂N₂O₂
• mdl: MFCD01851048
• 分子量: 156.184
• InChiKey: URPVILVQHHXONU-UHFFFAOYSA-N

物化性质

• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  DL-叔亮氨酸 在 盐酸 、 水 作用下， 生成 5-(tert-butyl)imidazolidine-2,4-dione
  参考文献：
  名称：

  Dakin, Journal of Biological Chemistry, 1926, vol. 67, p. 346

  摘要：

  DOI：

文献信息

• [EN] CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF<br/>[FR] DÉRIVÉS DE CALICHÉAMICINE ET CONJUGUÉS ANTICORPS-MÉDICAMENTS DE CEUX-CI
  申请人：PFIZER

  公开号：WO2018138591A1

  公开（公告）日：2018-08-02

  The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.

  本发明涉及新型calicheamicin衍生物，用作抗体-药物偶联物（ADC）的有效载荷，以及包含相同有效载荷-连接剂化合物和ADC化合物；涉及包含它们的药物组合物以及使用它们治疗诸如癌症等病理状态的方法。
• SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20200039989A1

  公开（公告）日：2020-02-06

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

  这项发明属于药物化学领域。具体来说，该发明涉及一类新型小分子，具有6,5-杂环结构（例如，具有咪唑吡啶、咪唑吡嘧啶、咪唑吡嗪、咪唑吡啶嗪、咪唑三嗪、苯并咪唑、苯并三唑、苯并异嗪、嘌呤、吲唑、三唑三嗪、三唑吡啶嗪、三唑吡嘧啶、三唑吡嗪、三唑四嗪、三唑吡啶、吡唑吡嗪、吡唑吡嘧啶、吡唑吡啶嗪、吡唑三嗪、吡唑吡啶、异嗪吡嗪、异嗪吡嘧啶、异嗪吡啶嗪、异嗪三嗪、或异嗪吡啶结构），其作为DYRK1A、DYRK1B和Clk-1的抑制剂，以及它们作为治疗阿尔茨海默病、唐氏综合征、糖尿病、胶质母细胞瘤、自身免疫疾病、癌症（例如，胶质母细胞瘤、前列腺癌）、炎症性疾病（例如，气道炎症）和其他疾病的治疗药物的用途。
• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR DE CANNABINOÏDES
  申请人：7TM PHARMA AS

  公开号：WO2009074782A1

  公开（公告）日：2009-06-18

  Compounds of formula (I) are modulators of cannabinoid receptor CB1, useful inter alia for treatment of obesity: Formula (I). Wherein:X is a bond, or a divalent radical selected from -C(R10)(R11)-*, -C(R10)(R11)-O-*, -C(R10)(R11)CH2-*, -C(R10)(R11)CH2-O-*, -CH2C(R10)(R11)-*, -CH2C(R10)(R11) -O-*. and -CH2-O-C(R10)(R11)-*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is a carboxyl isostere radical selected from the group specified; R3 is hydrogen, (C1-C)aIkyI or (C1C3)fluoroalkyl; R4 is a radical of formula -(AIk1)P-(Q1)r (L)s -Q2 wherein p, r, s, AIk1, L, Q1 and Q2 are as specified; or R3 and R4 taken together with the nitrogen to which they are attached form a cyclic amino ring of 4 to 7 ring atoms which is optionally substituted by a radical of formula -(L)s-Q2 wherein s, L and Q2 are as defined above, or by an optional substituent selected from hydroxy, methoxy, -NH2-, or mono- or di-(C1C3)alkylamino; R5, R6, R7 and R8 are each independently selected from hydrogen -F, -Cl, -Br, -CN, (C1-C3)alkyl, (C1C3)fluoroalkyl, cyclopropyl, and -OR9; R10 is hydrogen, (C1C3)alkyl, hydroxyl or NH2, and R11 is hydrogen or (C1-C3)alkyl; or R10 and R11 taken together with the carbon atom to which they are attached form a (C3-C5)cycloalkyl ring.

  式(I)的化合物是大麻素受体CB1的调节剂，可用于治疗肥胖：式(I)。其中：X是一个键，或者从-C(R10)(R11)-*、-C(R10)(R11)-O-*、-C(R10)(R11)CH2-*、-C(R10)(R11)CH2-O-*、-CH2C(R10)(R11)-*、-CH2C(R10)(R11) -O-*中选择的二价基团。和-CH2-O-C(R10)(R11)-*，其中星号表示连接到吡唑环的键；Z是从指定组中选择的羧基异构基团；R3是氢、(C1-C)aIkyI或(C1C3)氟烷基；R4是式-(AIk1)P-(Q1)r(L)s-Q2的基团，其中p、r、s、AIk1、L、Q1和Q2如指定；或者R3和R4与它们连接的氮一起形成一个含有4至7个环原子的环氨基环，该环可选地被式-(L)s-Q2中的基团或上述定义的s、L和Q2定义的基团取代，或者通过一个可选的取代基团选择自羟基、甲氧基、-NH2-或单或双-(C1C3)烷基胺；R5、R6、R7和R8分别独立地选择自氢、-F、-Cl、-Br、-CN、(C1-C3)烷基、(C1C3)氟烷基、环丙基和-OR9；R10是氢、(C1C3)烷基、羟基或NH2，R11是氢或(C1-C3)烷基；或者R10和R11与它们连接的碳原子一起形成一个(C3-C5)环烷基环。
• D-amino acid dehydrogenase and method of making D-amino acids
  申请人：Rozzell J. David

  公开号：US20080182972A1

  公开（公告）日：2008-07-31

  Polypeptides capable of catalyzing the reductive amination of a 2-ketoacid to its corresponding D-amino acid are provided. The polypeptides can be prepared by mutagenesis of, e.g., a diaminopimelate dehydrogenase. Also provided is a method of making a D-amino acid using a catalytically active polypeptide, wherein a 2-ketoacid is allowed to contact the polypeptide in the presence of a nicotinamide cofactor and ammonia or an ammonia source.

  提供了能够催化将2-酮酸还原氨基化为相应的D-氨基酸的多肽。这些多肽可以通过对二氨基戊二酸脱氢酶等进行突变来制备。还提供了一种使用具有催化活性的多肽制备D-氨基酸的方法，其中在存在烟酰胺辅因子和氨或氨源的情况下，允许2-酮酸与多肽接触。
• Vitamin D Receptor Modulators
  申请人：Shen Quanrong

  公开号：US20080119407A1

  公开（公告）日：2008-05-22

  The present invention relates to novel, non-secosteroidal, phenyl-benzoxazole compounds of Formula (I) wherein the variables R, R′, RP, RP 3 , L P1 , L P2 , ZP, RB, RB′, L XB and Z XB are as hereinafter defined, their preparation, pharmaceutical compositions, and methods of use.

  本发明涉及一种新型的非内环甾类苯基苯并咪唑化合物，其化学式为（I），其中变量R、R′、RP、RP3、LP1、LP2、ZP、RB、RB′、LXB和ZXB的定义如下，以及它们的制备、药物组合物和使用方法。